Recent News

• 06.10.2026 - Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
• 05.14.2026 - Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
• 04.28.2026 - Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
• 04.20.2026 - Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Recent Filings

• 06.05.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 06.05.2026 - ARS Annual Report to Security Holders
• 06.05.2026 - DEF 14A Other definitive proxy statements
• 05.27.2026 - 8-K Current report
• 05.26.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.26.2026 - PRE 14A Other preliminary proxy statements
• 05.19.2026 - EFFECT Notice of Effectiveness
• 05.18.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.15.2026 - 8-K Current report
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors